[CURRENT ISSUES OF BETA-BLOCKERS USE IN THE MANAGEMENT OF COVID-19 (REVIEW)]

Over the past two decades, the world has witnessed severe acute respiratory syndrome CoV (SARS-CoV), an underlying serious diseases, with a high rate of mortality in patients with comorbidities. Taking into account the clinical features of pulmonary edema, septic shock, deep vein thrombosis and pulmonary embolism, it seems that the severe course of COVID-19 can manifest itself in the body as a sympathetic storm and, possibly, can underlie many of the pathological processes that occur with COVID-19. It is the regulation of the RAAS by the adrenergic system may be crucially important in the course of COVID-19. This article outlines the benefits of beta blockers use in patients with COVID-19 based on the results of recent clinical and epidemiological studies. It has been shown that treatment with beta-blockers in this group of patients can potentially prevent the development of the disease at the earliest stages, reducing morbidity and mortality, preventing or reducing the development of pulmonary embolism, acute respiratory distress syndrome, pulmonary edema and complications of septic shock, fatal rhythm disturbances, etc. Of course, the final conclusions are somewhat premature and further research is needed to assess the positive effects of various beta-blockers use in the treatment of COVID-19.